2ⁿᵈ Edition of the Cancer R&D World Conference 2026

Scientific Sessions

Current Landscape and Future Directions of Oncology Research

Oncology Research has been a remarkable evolution, with breakthroughs noted in the fields of genomics, immunotherapy, and precision medicine. Advancement in molecular profiling and data-driven technologies allows for deep insights into tumor biology, thus enabling better and more personalized treatment methods. Artificial intelligence and bioinformatics help to revolutionize diagnostics, hasten drug discoveries, and optimize strategies to care for patients. Immune checkpoint inhibitors and other emerging therapies, such as CAR-T cell treatments, are redefining cancer management and control.

This scientific session in the Cancer Research and Development Conference 2026 will explore the changing face of oncology and elucidate new ideas that shape its future. Experts will investigate biomarker discovery, multi-omics data integration, and combination therapy development for overcoming resistance. Panel discussions also consider ethical issues, regulatory hurdles, and fair access to emerging therapies. We invite you to the next frontier in oncology research, where precision, innovation, and collaboration meet and redefine the future face of cancer care.

Related Sessions

Current Landscape and Future Directions of Oncology Research
Oncogenic Signaling Pathways and Therapeutic Targets
Emerging Biomarkers for Cancer Detection and Prognosis
Cancer Prevention and Early Detection Strategies
Immuno-Oncology and Cell-Based Therapies
Innovations in Immuno-Oncology
Cytokine Modulation and Immune Adjuvants in Cancer Immunotherapy
Cancer Vaccines
CAR-T Cell Therapy: Clinical Progress and Challenges
Next-Generation Cell and Gene Therapies in Oncology
Liquid Biopsy and Circulating Tumor DNA (ctDNA) Diagnostics
Companion Diagnostics
Artificial Intelligence and Machine Learning in Precision Oncology
Next-Generation Targeted Therapies: KRAS, HER2, BRAF, and NRAS
Overcoming Drug Resistance: Mechanisms and Solutions
Oncology Pipeline
Trends in Antibody–Drug Conjugates (ADCs)
Launch of Novel mAb Products for Cancer Therapy